CellCentric
58 employees on LinkedIn · 3 known investors
CellCentric is a clinical-stage biopharmaceutical company developing inobrodib, an oral small molecule inhibitor of the p300/CBP proteins, for the treatment of multiple myeloma and other cancers. The drug is being evaluated in clinical trials, including in combination with standard-of-care therapies for use in community care settings.
Investors · 3
Funding
SEC filings, press & company announcements$440M disclosed across 2 rounds · 2026
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does CellCentric do?
- CellCentric is a clinical-stage biopharmaceutical company developing inobrodib, an oral small molecule inhibitor of the p300/CBP proteins, for the treatment of multiple myeloma and other cancers. The drug is being evaluated in clinical trials, including in combination with standard-of-care therapies for use in community care settings.
- Who are CellCentric's investors?
- CellCentric's investors include Avego BioScience Capital, Future Planet Capital, Venrock.
- How much funding has CellCentric raised?
- CellCentric has disclosed $440M raised across 2 rounds.